This is a rare autoimmune disease that affects the kidneys and lungs. It happens when the body's immune system mistakenly attacks the basement membranes inside the blood vessels in these organs. This attack damages the kidneys and can cause bleeding in the lungs. It's often called Goodpasture Syndrome.
Every report comes from a Lived member, sent anonymously.
Have you had Plasmapheresis for Goodpasture Syndrome?
Goodpasture syndrome is a rare autoimmune disease in which the immune system makes antibodies that attack the kidneys and, often, the lungs. Doctors now usually call it anti-glomerular basement membrane disease, or anti-GBM disease. The glomerular basement membrane is a thin layer inside the glomeruli, the tiny filters in the kidney that clean waste and extra fluid from the blood. The same antibodies can damage similar tissue in the lung's air sacs. The result is inflammation of the kidney filters (glomerulonephritis) and, in roughly half of people, bleeding into the lungs. Early on, people often feel tired, weak, nauseated or generally unwell. Kidney involvement can cause pink or cola-colored urine, foamy urine, swelling in the legs and high blood pressure. Lung involvement can cause coughing up blood, a dry cough, chest pain and shortness of breath. What makes this disease important is its speed. Kidney damage can progress over days to weeks, and without treatment it can lead to kidney failure, dangerous lung bleeding and death. Prompt diagnosis and treatment greatly change the outcome. The name can be confusing. Some sources use "Goodpasture syndrome" more broadly for any illness that combines lung bleeding with kidney inflammation, including conditions that are not caused by anti-GBM antibodies. This page describes the antibody disease.
Researchers do not fully understand why the immune system turns against this tissue. A combination of inherited and environmental factors appears to be involved. Certain versions of HLA (human leukocyte antigen) genes, which help the immune system recognize what belongs to the body, make the disease more likely, while others seem protective. Having these genes does not mean someone will develop it. Things that irritate or injure the lungs may help set the disease off in a susceptible person. These include smoking, breathing in hydrocarbons (petroleum-based chemicals in gasoline, kerosene, paint thinner and some household products), respiratory infections, inhaled cocaine and metal dusts. These exposures are associated with the disease; they do not explain every case. Anti-GBM disease is very rare, with about one new case per million people each year. It most often appears in men in their 20s and women in their 60s, but it can occur at any adult age and only very rarely in children. Between 30% and 40% of people also have ANCA (anti-neutrophil cytoplasmic antibodies), a marker of a related form of blood vessel inflammation called ANCA vasculitis. These "double-positive" cases tend to occur in older adults.
Because the disease can move fast, diagnosis is usually handled urgently, often in a hospital. A urine test looks for blood and protein leaking through damaged kidney filters. Blood tests measure creatinine, a waste product that rises when the kidneys filter less, and estimate overall kidney function as eGFR (estimated glomerular filtration rate). A falling eGFR or a quickly rising creatinine signals that the kidneys are losing function. The key test is a blood test for anti-GBM antibodies, which are found in more than 90% of people with the typical form of the disease. A positive result points strongly to the diagnosis and guides treatment. Doctors usually also test for ANCA, because finding both antibodies changes long-term care. A kidney biopsy, in which a small piece of kidney is removed with a needle and examined under a microscope, can confirm the diagnosis by showing the antibody laid down in a characteristic smooth line along the kidney filters. It also shows how much of the kidney is still salvageable. A chest X-ray or CT (computed tomography) scan checks for bleeding in the lungs, which needs to be told apart from infection or fluid in the lungs. When someone is very ill and the disease is strongly suspected, doctors may start treatment before every result is back rather than lose time.
Treatment has two aims: remove the harmful antibodies already in the blood and stop the body from making more. The standard approach combines three treatments, usually started together. Plasma exchange (plasmapheresis) uses a machine to filter the liquid part of the blood, removing antibodies and replacing the fluid. It is typically done daily, often for about two weeks, until blood tests show the antibodies are gone. It requires a large intravenous line and can cause problems such as infection or blood clots at the line. Cyclophosphamide is an immune-suppressing medicine, originally a chemotherapy drug, that shuts down the cells making the antibodies. It is usually taken for about two to three months. Corticosteroids (steroids, given by drip at first and then as tablets) calm inflammation and are started at a high dose, then gradually tapered and usually stopped by about six months. Together these medicines weaken the body's defenses against infection and can lower blood counts, so people have regular blood tests and are usually given preventive medicines, such as an antibiotic to protect against a particular type of pneumonia, while on treatment. Cyclophosphamide can also harm a developing baby and can reduce fertility, sometimes permanently, so people who could become pregnant or father a pregnancy need effective contraception during treatment and for a period afterward, and can ask about options for preserving fertility, though this should not hold up urgent treatment. This regimen has been used since the 1970s and is supported by long clinical experience and observational studies rather than large randomized trials. Rituximab, an antibody medicine that removes the immune cells that make antibodies, is sometimes used when standard treatment is not enough or cannot be given, though evidence is limited. Newer approaches, including an enzyme called imlifidase that rapidly breaks down antibodies, are being tested in clinical trials. Supportive care matters as well. People with severe kidney damage may need dialysis, sometimes immediately, and people with serious lung bleeding may need help breathing in intensive care. Blood pressure medicines and limits on salt and fluid help control swelling. If the kidneys do not recover, long-term dialysis or a kidney transplant are options. A transplant is usually delayed until the antibodies have been absent from the blood for at least six months, because transplanting earlier carries a high risk of the disease attacking the new kidney. People who are double-positive for ANCA usually receive longer maintenance treatment afterward, because their disease comes back more often.
The first weeks are usually the most intense, with hospital care, daily plasma exchange and close monitoring. Lung bleeding responds well to treatment in the large majority of people, and it usually leaves no lasting lung damage. The kidneys are less predictable, and the biggest factor is how much function is left when treatment begins. Most people who do not yet need dialysis at the start keep working kidney function. For people who already need dialysis when treatment begins, recovery is uncommon: in published series, only about one in ten to one in five come off dialysis. Some people therefore live long term with dialysis or a transplant, and their outlook is similar to that of people whose kidneys failed for other reasons. Treatment usually lasts several months, as steroids are tapered and the immune system recovers, and side effects such as infections or raised blood sugar from steroids can be part of that period. Follow-up includes regular blood and urine tests to watch kidney function and confirm that the antibodies stay away. Unlike many autoimmune diseases, the typical form rarely comes back once it has been treated, and long-term immune-suppressing medicine is usually not needed. When it does return, it is often linked to continued smoking or exposure to fumes from hydrocarbons such as gasoline or solvents, so avoiding smoke, secondhand smoke and these vapors is an important part of staying well. People who also have ANCA face a higher chance of relapse and need longer follow-up.
See a doctor promptly if you notice blood in your urine, urine that looks pink, cola-colored or foamy, new swelling in your legs or face, or passing much less urine than usual, especially with tiredness or nausea. These can be signs of fast-moving kidney inflammation, and anti-GBM disease is time-sensitive, so ask to be seen the same day rather than waiting for a routine appointment. If you have this disease, are being evaluated for it, or have the urine changes above, coughing up blood or shortness of breath that is new or quickly getting worse needs emergency care right away, because bleeding in the lungs can become life-threatening. Call 911 if breathing is very difficult. During treatment, contact your care team promptly about a fever or other signs of infection, since the medicines weaken the body's defenses. After recovery, let your team know about any return of blood in the urine, swelling or coughing up blood, because relapse needs fresh assessment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Goodpasture Syndrome is like, what's helped you, or ask the community a question.